prikaz prve stranice dokumenta Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy
  Download
PDF 1.04 MB
Scientific paper - Review paper
Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy
International Journal of Molecular Sciences, 22 (2021), 9; 4327. https://doi.org/10.3390/ijms22094327
Verbanac, Donatella; Čeri, Andrea; Hlapčić, Iva; Shakibaei, Mehdi; Brockmueller, Aranka; Krušlin, Božo; Ljubičić, Neven; Baršić, Neven; Detel, Dijana; Batičić, Lara; Rumora, Lada; Somborac-Bačura, Anita; Štefanović, Mario; Ćelap, Ivana; Demirović, Alma; Petlevski, Roberta; Petrik, József; Grdić Rajković, Marija; Hulina-Tomašković, Andrea; Rako, Ivana; Saso, Luciano; Barišić, Karmela More authors...

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Verbanac, D., Čeri, A., Hlapčić, I., Shakibaei, M., Brockmueller, A., Krušlin, B. ... Barišić, K. (2021). Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy. International Journal of Molecular Sciences, 22. (9). doi: 10.3390/ijms22094327

Verbanac, Donatella, et al. "Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy." International Journal of Molecular Sciences, vol. 22, no. 9, 2021. https://doi.org/10.3390/ijms22094327

Verbanac, Donatella, Andrea Čeri, Iva Hlapčić, Mehdi Shakibaei, Aranka Brockmueller, Božo Krušlin, Neven Ljubičić, et al. "Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy." International Journal of Molecular Sciences 22, no. 9 (2021). https://doi.org/10.3390/ijms22094327

Verbanac, D., et al. (2021) 'Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy', International Journal of Molecular Sciences, 22(9). doi: 10.3390/ijms22094327

Verbanac D, Čeri A, Hlapčić I, Shakibaei M, Brockmueller A, Krušlin B, and sur.. Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy. International Journal of Molecular Sciences [Internet]. 2021 April 21 [cited 2024 November 09];22(9). doi: 10.3390/ijms22094327

D. Verbanac, et al., "Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy", International Journal of Molecular Sciences, vol. 22, no. 9, April 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:556870. [Accessed: 09 November 2024]

Metadata
Title (english)Profiling Colorectal Cancer in the Landscape Personalized Testing—Advantages of Liquid Biopsy
AuthorDonatella Verbanac
AuthorAndrea Čeri
AuthorIva Hlapčić
AuthorMehdi Shakibaei
AuthorAranka Brockmueller
AuthorBožo Krušlin
AuthorNeven Ljubičić
AuthorNeven Baršić
AuthorDijana Detel
AuthorLara Batičić
AuthorLada Rumora
AuthorAnita Somborac-Bačura
AuthorMario Štefanović
AuthorIvana Ćelap
AuthorAlma Demirović
AuthorRoberta Petlevski
AuthorJózsef Petrik
AuthorMarija Grdić Rajković
AuthorAndrea Hulina-Tomašković
AuthorIvana Rako
AuthorLuciano Saso
AuthorKarmela Barišić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pathology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Drug-specific therapeutic approaches for colorectal cancer (CRC) have contributed to significant improvements in patient health. Nevertheless, there is still a great need to improve the personalization of treatments based on genetic and epigenetic tumor profiles to maximize the quality and efficacy while limiting cytotoxicity. Currently, CEA and CA 19-9 are the only validated blood biomarkers in clinical practice. For this reason, laboratories are trying to identify new specific prognostics and, more importantly, predictive biomarkers for CRC patient profiling. Thus, the unique landscape of personalized biomarker data should have a clinical impact on CRC treatment strategies and molecular genetic screening tests should become the standard method for diagnosing CRC. This review concentrates on recent molecular testing in CRC and discusses the potential modifications in CRC assay methodology with the upcoming clinical application of novel genomic approaches. While mechanisms for analyzing circulating tumor DNA have been proven too inaccurate, detecting and analyzing circulating tumor cells and protein analysis of exosomes represent more promising options. Blood liquid biopsy offers good prospects for the future if the results align with pathologists’ tissue analyses. Overall, early detection, accurate diagnosis and treatment monitoring for CRC with specific markers and targeted molecular testing may benefit many patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleInternational Journal of Molecular Sciences
Numberingvol. 22, no. 9, 4327
e-ISSN1422-0067
DOIhttps://doi.org/10.3390/ijms22094327
URN:NBNurn:nbn:hr:105:556870
Publication2021-04-21
ProjectNumber: IP-2019-04-4624
Title (croatian): Gensko, proteinsko i RNA profiliranje kolorektalnog karcinoma primjenom tekuće biopsije
Title (english): Genetic, Protein and RNA Profiling of Colorectal Cancer Using Liquid Biopsy
Acronym: CRCMolProfil
Leader: Karmela Barišić
Jurisdiction: Croatia
Funding stream: IP
Document URLhttps://www.mdpi.com/1422-0067/22/9/4327
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2021-11-03 12:18:04